Cornell Pochily Investment Advisors Inc. Buys 1,615 Shares of Kenvue Inc. (NYSE:KVUE)

Cornell Pochily Investment Advisors Inc. increased its stake in shares of Kenvue Inc. (NYSE:KVUE) by 17.4% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 10,917 shares of the company’s stock after acquiring an additional 1,615 shares during the period. Cornell Pochily Investment Advisors Inc.’s holdings in Kenvue were worth $233,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of KVUE. Grove Bank & Trust lifted its holdings in shares of Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after acquiring an additional 947 shares during the period. Riverview Trust Co bought a new stake in shares of Kenvue in the 3rd quarter worth about $30,000. Geneos Wealth Management Inc. acquired a new stake in shares of Kenvue during the 4th quarter worth about $29,000. Ashton Thomas Securities LLC bought a new position in Kenvue during the 3rd quarter valued at about $35,000. Finally, Fortitude Family Office LLC boosted its position in Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after buying an additional 777 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Price Performance

KVUE opened at $20.79 on Monday. The company has a fifty day moving average price of $22.14 and a two-hundred day moving average price of $21.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The firm has a market capitalization of $39.85 billion, a PE ratio of 37.79, a P/E/G ratio of 1.99 and a beta of 1.46. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. The company had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company’s revenue for the quarter was down .4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.31 EPS. As a group, analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be issued a $0.205 dividend. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.95%. Kenvue’s dividend payout ratio (DPR) is presently 149.09%.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on KVUE shares. Piper Sandler raised shares of Kenvue from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $21.00 to $26.00 in a report on Monday, January 6th. Bank of America lifted their price objective on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. JPMorgan Chase & Co. increased their target price on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Citigroup cut their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Wednesday, January 15th. Finally, Royal Bank of Canada raised shares of Kenvue from a “hold” rating to a “moderate buy” rating in a report on Monday, December 9th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $23.08.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.